August 2, 2024 06:00 AM EDT

Exclusive: Ultragenyx secures first funds for Alzheimer's gene therapy spinout

Kyle LaHucik

Senior Reporter

Rare disease specialist Ultragenyx reeled in a $14 million seed round for its Alzheimer’s gene therapy spinout Amlogenyx, the company exclusively told Endpoints News. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: Ultragenyx secures first funds for Alzheimer's gene therapy spinout

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Summit's Phase 3 data back up biotech's boasts of beating Keytruda in lung cancer

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

Ex­clu­sive: Ul­tragenyx se­cures first funds for Alzheimer's gene ther­a­py spin­out

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Ultragenyx secures first funds for Alzheimer's gene therapy spinout